The UW Carbone Cancer Center (UWCCC) participates in the Big Ten Cancer Research Consortium. The Consortium unites Big Ten cancer centers to transform the conduct of cancer research through collaborative, hypothesis-driven, highly translational oncology trials. The Consortium’s strengths lie in leveraging the scientific and clinical expertise of Big Ten universities.
Benefits of UWCCC membership to the Consortium includes:
- Expedited contracting by virtue of membership
- Planned consolidated IRB review
- Organized clinical trial working groups
- Ability to share specimens with clinically annotated data
- Avenue for development of junior faculty
- Opportunity to quickly open trials across 13 academic institutions
In addition to UWCCC, the following universities and cancer centers comprise the Big Ten Cancer Research Consortium:
- Indiana University (Indiana University Melvin and Bren Simon Comprehensive Cancer Center)
- Michigan State University (Breslin Cancer Center)
- Northwestern University (Robert H. Lurie Comprehensive Cancer Center)
- The Ohio State University (The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute)
- Penn State University (Penn State Hershey Cancer Institute)
- Purdue University (Purdue University Center for Cancer Research)
- Rutgers University (Rutgers Cancer Institute of New Jersey)
- University of Illinois at Chicago (University of Illinois Cancer Center)
- University of Illinois at Urbana-Champaign (The Cancer Center at Illinois)
- University of Iowa (Holden Comprehensive Cancer Center)
- University of Maryland (Marlene and Stewart Greenebaum Comprehensive Cancer Center)
- University of Michigan (University of Michigan Rogel Cancer Center)
- University of Minnesota (Masonic Cancer Center)
- University of Nebraska (Fred & Pamela Buffett Cancer Center)
News & Developments
Big Ten CRC Press Releases
-
Summit highlights 10 years of Big Ten CRC collaboration
December 4, 2023 -
Big Ten CRC Diversity Committee launch Podcast
September 6, 2023 -
Big Ten Cancer Research Consortium Hosts 2023 Summit
September 6, 2023 -
Meet Big Ten CRC at 2023 ASCO Annual Meeting
May 1, 2023 -
Redefining Treatment for Blood Cancers with CAR-T Therapy
February 15, 2023
UW @ the Big Ten
“Game Changing” Recent Advances in Lung Cancer Treatment
When medical oncologist Ticiana Leal, MD, spoke at the UW Carbone Cancer Center’s Lung Cancer Awareness Night in late 2018, she brought her cautious optimism to the patients and families in attendance. “In the past year alone, there …
July 1, 2019Member Feature: University of Wisconsin
Imagine having surgery to remove a tumor, and by the time you’ve recovered from the operation, your oncologist has determined a specific drug regimen that is targeted to treat your cancer. “If you get diagnosed …
July 1, 2019Big Ten CRC study to help determine maximum dosage of ruxolitinib when combined with nivolumab in Hodgkin lymphoma patients
A phase I Big Ten Cancer Research Consortium study for adult patients with relapsed or refractory Classical Hodgkin lymphoma is open for accrual at Masonic Cancer Center, University of Minnesota; the University of Illinois Cancer …
March 8, 2019Dr. Wisinski joins Steering Committee
Kari Wisinski, MD, a breast cancer specialist with the UW Carbone Cancer Center, has been named to the Steering Committee of the Big Ten Cancer Research Consortium (Big Ten CRC). In that role, she will serve as the …
November 20, 2018- More Big Ten posts